Rial Maribel Botana, Rodríguez Irene Lojo, Roibás Cecilia Mouronte, Fernández Virginia Leiro, Delgado Manuel Núñez, Barreira Ángel Salgado, Torrado Andrea Pereira, Villar Alberto Fernández
Unidad de Técnicas Broncopleurales, Servicio de Neumología, Hospital Álvaro Cunqueiro, Área Sanitaria de Vigo, Vigo, Pontevedra, Spain; Grupo de Investigación NeumoVigo I+i, Instituto de Investigación Sanitaria Galicia Sur, Hospital Álvaro Cunqueiro, Vigo, Pontevedra, Spain.
Unidad de Técnicas Broncopleurales, Servicio de Neumología, Hospital Álvaro Cunqueiro, Área Sanitaria de Vigo, Vigo, Pontevedra, Spain.
Arch Bronconeumol. 2020 Dec;56(12):784-791. doi: 10.1016/j.arbr.2020.10.003. Epub 2020 Nov 5.
Current evidence on the diagnostic yield and safety of pleural cryobiopsy (CB) is based on a series of heterogeneous studies with limited cohorts. A pooled analysis of these studies could improve the evidence and contribute to a better understanding of this new technique.
We performed a systematic review and meta-analysis of published studies that included data on the yield and diagnostic safety of pleural CB compared with procedures performed using conventional flexible forceps. The heterogeneity of the analysis was evaluated by determining the I2 index, while study quality was measured with the QUADAS-2 tool.
Seven studies involving 356 patients were used for the final evaluation. In 55.6%, the etiology of the pleural effusion was malignant, 61.1% of which were lung cancer. The diagnostic yield of pleural CB was 95% (95% CI 92-97) vs. 91% (95% CI 87-94) with conventional flexible forceps (P = .019). Mild bleeding was reported in 67% of CB procedures (95% CI 62-72) compared with 85% of conventional flexible forceps procedures (95% CI 79-90) (P < .001). CB specimens were larger, and fewer artifacts were detected. A pooled analysis of the detection of molecular changes could not be performed. Heterogeneity was moderate to high, although the quality of the studies was acceptable.
Pleural CB is a safe technique with a high yield for etiological diagnosis of pleural effusion, and larger specimens with fewer artifacts are obtained. Molecular determinations should be investigated in more depth.
目前关于胸膜冷冻活检(CB)诊断率和安全性的证据基于一系列队列有限的异质性研究。对这些研究进行汇总分析可完善证据,并有助于更好地理解这项新技术。
我们对已发表的研究进行了系统评价和荟萃分析,这些研究纳入了胸膜CB与使用传统可弯曲活检钳操作相比的诊断率和诊断安全性数据。通过确定I2指数评估分析的异质性,同时使用QUADAS-2工具衡量研究质量。
七项涉及356例患者的研究用于最终评估。55.6%的胸腔积液病因是恶性的,其中61.1%为肺癌。胸膜CB的诊断率为95%(95%CI 92-97),而传统可弯曲活检钳的诊断率为91%(95%CI 87-94)(P = 0.019)。67%的CB操作报告有轻度出血(95%CI 62-72),而传统可弯曲活检钳操作的这一比例为85%(95%CI 79-90)(P < 0.001)。CB标本更大,检测到的伪像更少。无法对分子变化检测进行汇总分析。尽管研究质量可接受,但异质性为中度至高度。
胸膜CB是一种安全技术,对胸腔积液病因诊断的阳性率高,且可获得更大、伪像更少的标本。分子检测应进行更深入的研究。